Filariasis
(Elephantiasis, river blindness/onchocerciasis)
Material: | EDTA-monovette for “thick drop smear” and blood slide. Depending on species, microfilaria periodically remain in the peripheral blood. This should be considered at the time of extraction (Brugia and Wucheria: 21:00 – 2:00, Loa loa: 11:00 – 13:00). Precise microscopic detection of filaria in special laboratories. Pathogen detection: Demonstration of Onchocerca volvulus from skin excisions (skin snips), special laboratory/external service Antibody-demonstration: 1 ml serum, external service |
Methods: |
Mikroskopie → Hellfeldmikroskopie Ligandenassays → Enzyme Linked Immunosorbent Assay (ELISA) Ligandenassays → Immunoblot | Criteria for evaluation | IgG: < 10 MONA |
Indication | Suspicion of lymphatic filariasis, suspicion of loiasis, suspicion of onchocerciasis |
Comment | Please also refer to: “Nematodes” |
Please note | Wucheria bancrofti and Brugia malayi/timori: Pathogens of lymphatic filariasis; transmission by mosquitos, distribution areas are Central Africa, South America, India and South East Asia. Prepatent period of several months. Lymphangitis and lymphadenitis, fever, eosinophilia, swelling of various skin- and body parts, which chronically lead to elephantiasis, chyluriasis and hydrocele. Loa loa: Pathogen of loiasis, transmission by chrysops-horseflies, spread is restricted to West- and Central Africa, prepatent period 1 – 4 years. Migrating edematous skin swelling, conjunctival infection. Onchocerca volvulus (River blindness/onchocerciasis): Pathogen of onchocerciasis, distribution areas are West- and Central Africa, some countries in Central- and South America and Yemen, transmission by black flies. Prepatent period 1 – 2 years. Subcutaneous nodes, itching, corneal clouding. Serology: Nematode blot. Cross-reactions with other nematodes and echinococcus are possible. |
External services | ja |
More Results for the letter F
- Factor II activity (FACT01)
- Prothrombin
- Factor II mutation (FACT02)
- Prothrombin mutation G20210A
- Factor IX activity (FACT11)
- Factor V activity (FACT03)
- Factor V mutation Leiden (FACT04)
- Mutation: G1691A
- Factor VII activity (FACT05)
- Factor VIII activity (FACT06)
- Factor VIII inhibitor (FACT10)
- Factor VIII ristocetin cofactor (von Willebrand factor activity) (FACT08)
- vWF:activity
- Factor VIII von Willebrand factor antigen (FACT07)
- vWF:Ag
- Factor VIII von Willebrand multimers (FACT09)
- Factor X activity (FACT12)
- Factor XI activity (FACT13)
- Factor XII activity (FACT14)
- Hageman-Factor
- Factor XIII activity (FACT15)
- Syn.: fibrin stabilising factor
- Factor–II–activity (FAK2)
- Prothrombin
- Factor-II-mutation (FAK2GM)
- Prothrombin mutation G20210A
- Factor-IX-activity (FAK9)
- Factor-V-activity (FAK5)
- Factor-V-mutation Leiden (FAK5GM)
- Mutation: G1691A
- Factor-VII-activity (FAK7)
- Factor-VIII-activity (FAK8)
- Factor-VIII-inhibitor (FAK8IN)
- Bethesda assay
- Factor-X-activity (FAK10)
- Factor-XI-activity (FAK11)
- Factor-XII-activity (FAK12)
- Hageman factor
- Factor-XIII-activity (FAK13)
- Fibrin-stabilizing factor
- Fasciola hepatica (FASCI, FASCG)
- Common liver fluke
- Fat, total in stool (FETT1)
- Fatty acids, long-chained (LAFS)
- LCFA